MRK vs MXCT
MRK: Global pharmaceutical and vaccine leader with oncology, infectious disease, and animal health franchises, anchored by blockbuster immunotherapy Keytruda. MXCT: MaxCyte enables cell therapy development through proprietary electroporation technology that delivers molecules into cells for engineering next-generation cell-based medicines.
Side-by-side fundamentals
| Metric | MRK | MXCT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $127.47 | $1.14 | |
| Market cap as of 2026-07-23 | $315.3B | $125M | |
| P/E as of 2026-07-23 | 35.29 | n/a | |
| PEG as of 2026-07-23 | 4.34 | n/a | |
| Net margin as of 2026-07-23 | +13.6% | -121.2% | MRK higher |
| Gross margin as of 2026-07-23 | +78.1% | +80.5% | MXCT higher |
| Operating margin as of 2026-07-23 | +18.2% | -141.8% | MRK higher |
| ROE as of 2026-07-23 | +17.9% | -22.0% | MRK higher |
| ROA as of 2026-07-23 | +7.0% | -18.9% | MRK higher |
| Debt / equity as of 2026-07-23 | 1.07 | 0.00 | MXCT lower |
| Revenue growth (YoY) as of 2026-07-23 | +2.9% | -14.3% | MRK higher |
| Revenue CAGR (3y) SEC XBRL | +3.1% | -9.3% | MRK higher |
| Dividend yield as of 2026-07-23 | +2.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.21 | 1.48 | |
| 1-year return as of 2026-07-22 close | +56.2% | -49.1% | MRK higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.